Interlink is a binary micro-cap turnaround: a proposed profitable acquisition and medical printed-electronics pipeline could transform the business, but execution, dilution, customer concentration, and China-linked supply risk define the downside.
Interlink Electronics, Inc. (NASDAQ: LINK) is navigating a complex structural pivot from a micro-cap supplier of legacy human-machine interface components to a diversified, vertically integrated provider of printed electronics, electrochemical gas sensors, smart textiles, and high-performance manufacturing solutions.[1, 2, 3] Historically, the business has been constrained by a sub-scale organic revenue footprint, high customer concentration, and persistent operating losses.[4, 5, 6] However, a series of structural, operational, and capital markets developments in late 2025 and the first half of 2026 have significantly altered the long-term investment horizon.[1, 5, 7]
The primary operational catalyst is a non-binding Letter of Intent (LOI) executed on May 11, 2026, to acquire an established provider of high-performance manufacturing solutions serving mission-critical sectors, including aerospace, defense, semiconductors, and photonics.[7, 8] The target generated more than $33 million in revenue and approximately $4 million in EBITDA in fiscal year 2025.[7, 8] Given Interlink’s legacy FY 2025 revenue of $11.890 million, the successful consummation of this reverse-takeover-scale transaction would immediately expand the combined entity's annual revenue base to over $45 million, introduce robust cash flow, and establish a baseline of profitability.[4, 7]
In addition to this potential acquisition, Interlink is advancing several high-value organic projects.[1] The company is preparing to enter clinical trials with its newly developed diagnostic test strip electrodes for connected point-of-care testing and home-testing platforms.[1] It is also developing third-generation smart textile wearable products designed for FDA-approved therapeutic applications.[1] To support these initiatives, a dedicated R&D and manufacturing facility is scheduled to open in South Yorkshire, England, in July 2026.[1]
On the capital structure front, the transition is supported by the conversion of all outstanding Series A Convertible Preferred Stock into common stock in October 2025.[5] This conversion retired a $5.0 million liquidation preference and eliminated $400,000 in annual preferred dividends, materially improving net income attributable to common stockholders.[5, 9] Furthermore, Interlink’s selection for inclusion in the Russell Microcap Index, effective June 29, 2026, is expected to enhance institutional visibility and drive steady passive investment flows.[10, 11]
While Q1 2026 financial results indicate a positive trend—evidenced by a 15.4% year-over-year revenue increase to $3.07 million and gross margin expansion to 43.5%—the legacy business remains in a net loss position.[1] Achieving sustained profitability depends on the successful execution, financing, and integration of the pending acquisition, alongside the timely commercialization of its smart textile and medical diagnostic pipelines.[1, 7, 8]
Interlink’s business model historically focused on its proprietary Force Sensing Resistor (FSR) technology, which captures three-dimensional force and pressure grids across industrial, medical, and consumer interfaces.[3] While FSR technology remains a core component of the business, the company is shifting its focus toward higher-margin, application-specific solutions.[1, 4] This reorientation is being driven by strategic investments in materials science, conductive inks, and printed sensor systems.[1, 7, 12]
The acquisition of Calman Technology in March 2023 established a localized manufacturing and design presence in Europe, expanding Interlink’s printed electronics and membrane keyboard capabilities.[13] To build on this footprint, the company acquired Conductive Transfers, bringing in advanced conductive transfer technology that allows complex circuits and sensor grids to be printed onto flexible substrates, such as smart textiles and fabrics.[1, 14, 15] These technologies are being leveraged to develop a third-generation wearable product used in an FDA-approved muscle stimulation therapeutic device.[1]
To scale the commercialization of these smart textiles and wearables, Interlink is launching a dedicated R&D and production facility in South Yorkshire, England, at the beginning of July 2026.[1] This facility is designed to meet growing European demand for integrated electronic wearables in healthcare, industrial safety, and sporting applications.[1]
A key driver of Interlink’s mid-term growth strategy is its expansion into the healthcare diagnostics market.[1, 5] The company is leveraging its printed electronics expertise to develop electrodes for intelligent test strips used in connected point-of-care and home-testing diagnostic platforms.[1] These diagnostic test strip electrodes are slated to enter clinical trials in the near term.[1] Under this development timeline, initial manufacturing is anticipated to commence in late 2026, with significant volume production ramping up in fiscal year 2027, provided the diagnostic products secure regulatory approval.[1]
In addition, the gas-sensor business has expanded into high-value environmental and industrial safety applications.[15] The launch of advanced odor and carbon monoxide detectors, including its proprietary 4-Series detectors, targets municipal infrastructure, environmental monitoring, and workplace safety markets, diversifying Interlink's historical reliance on consumer electronics.[15]
The market opportunity for printed and flexible electronics is large and expanding.[16, 17] The global printed electronics market size was valued at $19.46 billion in 2025 and is projected to reach $39.85 billion by 2030, representing a compound annual growth rate (CAGR) of 15.4%.[16] This expansion is driven by the growing demand for thin, flexible, and lightweight electronic components in internet of things (IoT) devices, medical biosensors, and electric vehicle battery systems.[16, 17] Within this landscape, the printed wearable devices market alone is expected to expand to $5.8 billion by 2028.[12]
Despite these favorable tailwinds, Interlink operates in a highly fragmented and capital-intensive sector that requires continuous investment in research and development.[16, 18] The company faces competition from two primary groups:
| Competitor Tier | Primary Competitors | Competitive Advantage / Moat |
|---|---|---|
| Tier 1: Global Diversified Conglomerates | Honeywell, TE Connectivity, Amphenol, Sensata Technologies [19] | Massive capital reserves, global distribution networks, and established long-term automotive/aerospace supply relationships. |
| Tier 2: Specialized Custom Providers | Tangio Printed Electronics, Tekscan, Pressure Profile Systems [19] | High specialization in force-sensing resistors, tactile pressure sensors, and rapid prototyping capabilities. |
Interlink attempts to defend its competitive position through its vertically integrated manufacturing model and its intellectual property portfolio, which includes 49 issued patents and 14 pending patent applications.[4, 20]
An analysis of Interlink’s financial performance over the past five fiscal years reveals a clear pattern: a period of inorganic growth followed by cost adjustments and margin compression.[4, 21]
| Statement of Operations Line Item | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|
| Revenue ($ Millions) | $7.48 [21] | $7.49 [21] | $13.94 [21] | $11.68 [21] | $11.89 [5] |
| Revenue Growth (YoY %) | +8.57% [21] | +0.20% [21] | +86.04% [21] | -16.22% [21] | +1.81% [21] |
| Cost of Revenue ($ Millions) | $3.42 [22] | $3.63 [22] | $7.38 [22] | $6.83 [22] | $7.26 [23] |
| Gross Profit ($ Millions) | $4.06 [22] | $3.86 [22] | $6.56 [22] | $4.85 [22] | $4.63 [4] |
| Gross Profit Margin (%) | 54.27% [22] | 51.53% [22] | 47.05% [22] | 41.49% [22] | 38.90% [4] |
| R&D Expense ($ Millions) | N/A | $0.67 [24] | $0.44 [24] | $2.05 [24] | $1.83 [24] |
| SG&A Expense ($ Millions) | $4.14 [22] | $4.53 [22] | $7.00 [22] | $6.90 [22] | $4.96 [23] |
| Operating Loss ($ Millions) | $(0.08) [24] | $(0.67) [24] | $(0.44) [24] | $(2.05) [5] | $(1.83) [5] |
| Net Loss ($ Millions) | $(0.78) [24] | $1.27 [24] | $(0.38) [24] | $(1.98) [5] | $(1.62) [5] |
| Net Loss to Common ($ Millions) | $(0.78) [24] | $1.27 [24] | $(0.78) [24] | $(2.38) [5] | $(1.95) [5] |
| Adjusted EBITDA ($ Millions) | N/A | N/A | N/A | $(1.07) [5] | $(0.89) [5] |
The jump in FY 2023 revenue to $13.94 million was driven by the post-merger consolidation of Calman Technology.[13, 21] However, subsequent organic volume declines led to a 16.22% revenue contraction in FY 2024.[21]
Gross profit margins compressed from 54.27% in FY 2021 to 38.90% in FY 2025.[4, 22] This margin compression was driven by unfavorable product mix shifts and rising overhead costs, further exacerbated in FY 2025 by a strengthened Chinese Yuan (CNY) relative to the US Dollar (USD), which inflated production expenses at the company's Shenzhen facility.[5]
In response, management implemented cost-control measures in FY 2025, reducing R&D spending by 26.7% through headcount reductions and lower consultant costs, while also cutting SG&A overhead.[4]
First-quarter results reported on May 14, 2026, show positive near-term momentum, characterized by top-line growth and a narrowing of operating losses.[1]
| Metric ($ in thousands, except per share) | Three Months Ended Mar 31, 2026 | Three Months Ended Mar 31, 2025 | YoY Change (%) |
|---|---|---|---|
| Revenue | $3,074 [1] | $2,664 [1] | +15.39% [1] |
| Cost of Revenue | $1,738 [25] | $1,715 [25] | +1.34% [25] |
| Gross Profit | $1,336 [1] | $949 [1] | +40.78% [1] |
| Gross Margin (%) | 43.46% [1, 26] | 35.62% [1, 26] | +7.84% [1, 26] |
| R&D Expense | $303 [25] | $434 [25] | -30.18% [25] |
| SG&A Expense | $1,483 [25] | $1,364 [25] | +8.72% [25] |
| Loss from Operations | $(450) [1] | $(849) [1] | -47.00% [1] |
| Net Loss | $(338) [1] | $(805) [1] | -58.01% [1] |
| Basic & Diluted EPS | $(0.02) [1] | $(0.06) [1] | +66.67% [1] |
| Adjusted EBITDA | $(168) [1] | $(623) [1] | -73.03% [1] |
The 15.39% year-over-year revenue increase in Q1 2026 was driven by higher shipments of traditional force-sensing and printed electronics products, which offset minor declines in gas-sensor products.[1]
The gross margin expansion of 784 basis points to 43.46% reflects a higher-margin product mix and improved operating scale.[1] R&D expenses continued to decline, dropping 30.18% to $303k, helping narrow the operating loss to $(450)k and the Adjusted EBITDA loss to $(168)k.[1, 25]
Interlink's balance sheet remains liquid, but capital reserves are operating under near-term constraints.[1, 25]
| Balance Sheet Line Item ($ in thousands) | March 31, 2026 | December 31, 2025 | Absolute Change |
|---|---|---|---|
| Cash & Cash Equivalents | $2,106 [25] | $2,724 [25] | $(618) [25] |
| Accounts Receivable, net | $1,709 [25] | $1,542 [25] | $167 [25] |
| Inventories | $1,987 [25] | $1,801 [25] | $186 [25] |
| Prepaids & Other Current Assets | $280 [25] | $236 [25] | $44 [25] |
| Total Current Assets | $6,082 [25] | $6,303 [25] | $(221) [25] |
| Goodwill & Net Intangible Assets | $3,678 [25] | $3,919 [25] | $(241) [25] |
| Total Assets | $11,142 [25] | $11,738 [25] | $(596) [25] |
| Accounts Payable & Accrued Liabilities | $1,344 [25] | $1,315 [25] | $29 [25] |
| Current Lease Liabilities & Taxes | $333 [25] | $348 [25] | $(15) [25] |
| Total Current Liabilities | $1,677 [25] | $1,663 [25] | $14 [25] |
| Long-Term Liabilities | $724 [25] | $854 [25] | $(130) [25] |
| Total Liabilities | $2,401 [25] | $2,517 [25] | $(116) [25] |
| Accumulated Deficit | $(54,133) [25] | $(53,795) [25] | $(338) [25] |
| Total Stockholders' Equity | $8,741 [25] | $9,221 [25] | $(480) [25] |
While the company has a solid current ratio of 3.63x and is operating with low levels of long-term debt (debt-to-equity ratio of 0.08), its absolute cash position declined 22.7% during Q1 2026 to $2.11 million.[25, 27] This cash reduction was driven by operating cash outflows and working capital adjustments, including an inventory increase to $1.99 million to support contracted order backlogs.[25]
Despite these near-term cash demands, the balance sheet exhibits moderate structural durability, with an Altman Z-Score of 11.42 (suggesting low bankruptcy risk) and a Piotroski F-Score of 3.[27]
At the current share price of $4.61, Interlink has an equity market capitalization of $75.92 million and an enterprise value ($EV$) of $74.53 million, calculated as follows [27, 28]:
$EV = \text{Market Cap} + \text{Debt} - \text{Cash}$
$EV = 75.92 + 0.72 - 2.11 = 74.53 \text{ million USD} \quad \text{[27, 28]}$
Based on its TTM revenue of $12.30 million, the stock trades at an elevated trailing $EV/\text{Sales}$ ratio of $6.06\text{x}$ and a price-to-sales ($P/\text{S}$) ratio of $6.17\text{x}$.[27, 28] These valuations reflect investor expectations for a successful long-term turnaround, as the company remains unprofitable.[1]
However, the proposed acquisition target radically alters these valuation dynamics.[7] The target generated more than $33 million in revenue and $4 million in EBITDA in fiscal year 2025.[7] Assuming the transaction is completed on typical micro-cap terms (an estimated transaction value of $22.0 million to $28.0 million, implying an EBITDA multiple of $5.5\text{x}$ to $7.0\text{x}$), the pro-forma combined entity would exhibit a fundamentally different financial profile:
$\text{Pro-forma Combined TTM Revenue} \approx 12.30 \text{M (LINK)} + 33.00 \text{M (Target)} = 45.30 \text{ million USD} \quad \text{[7, 28]}$
$\text{Pro-forma Combined EBITDA} \approx (0.43)\text{M (LINK TTM Adjusted)} + 4.00\text{M (Target)} = 3.57 \text{ million USD} \quad \text{[1, 5, 7]}$
This transaction would compress the combined entity's implied $EV/\text{Sales}$ multiple from $6.06\text{x}$ to approximately $1.64\text{x}$. However, because the acquisition will be financed through a combination of debt and equity, final valuation metrics will depend on the dilution resulting from any new share issuances.[7, 8]
For example, if Interlink funds $12.0 million of the purchase price via equity at the current price of $4.61, it would issue approximately $2.60$ million new common shares, diluting existing stockholders by roughly 16.5%.[27, 28] If the balance is funded with senior secured debt, the consolidated interest expense would also rise, placing additional demands on the combined entity's operating cash flow.[7]
Interlink remains exposed to high customer concentration risk, which represents a key operational vulnerability.[10]
Accounts Receivable Concentration Profile:
- Largest Customer Share (Mar 31, 2026): 23% of total accounts receivable [6]
- Largest Customer Share (Dec 31, 2025): 23% of total accounts receivable [6]
A consistent 23% concentration of accounts receivable with a single customer exposes the company to notable downside risk.[6] Any change in this customer's product design, contract renewal terms, or financial health would directly impact Interlink's revenue stability and working capital requirements.
Interlink’s global manufacturing and assembly footprint, which includes a primary high-volume production facility in Shenzhen, China, exposes the company to geopolitical and trade policy risks.[4, 5] These operations face several ongoing vulnerabilities:
* Tariff and Trade Policy Risks: Changes in US-China import tariffs on electronic components, printed circuit boards, and sensors can directly inflate the cost of goods sold for items shipped to North American end-users.[15]
* Foreign Exchange Sensitivity: Production expenses at the Shenzhen plant are denominated in Chinese Yuan (CNY).[5] In FY 2025, a strengthening CNY relative to the USD increased the cost of Chinese manufacturing, contributing to gross margin compression.[5]
* Raw Material Inflation: The production of printed electronics relies on specialized raw materials, including silver conductive inks.[12] Sustained inflation in global silver prices directly increases the manufacturing costs of conductive transfer products and smart textile overlays, challenging margin stability.[12]
Interlink's corporate governance structure features highly concentrated ownership and control.[27, 29]
Control and Voting Power Distribution:
- CEO Steven N. Bronson Ownership: 11,847,607 common shares [29]
- Total Common Shares Outstanding: 15,750,007 [30]
- Bronson Equity and Voting Control: 75.22% [29, 30]
- Total Public Float: 5.64 million shares [27, 28]
With CEO Steven N. Bronson directly controlling 75.22% of the outstanding common stock, minority shareholders have minimal voting influence.[29, 30] This high concentration can limit trading liquidity in the public market.[27, 28] Additionally, Bronson serves as the top executive at several other publicly traded or quoted entities, including Qualstar Corporation and BKF Capital Group, which could potentially divide his operational focus.[20]
The board consists of three independent directors: Joy C. Hou, David J. Wolenski, and Maria N. Fregosi, who have each served for over five years, providing some oversight stability.[31] However, the approval of the 2026 Omnibus Incentive Plan at the May 19, 2026, stockholder meeting, which authorized up to 1.5 million shares for equity-based compensation, introduces potential near-term dilution risk for public shareholders.[31]
The five-year scenario matrix models possible operational and valuation paths for Interlink based on the integration of the proposed acquisition and the commercialization of its product pipeline.[1, 7]
| Five-Year Forecast Metric | Year 1 (FY 2026) | Year 2 (FY 2027) | Year 3 (FY 2028) | Year 4 (FY 2029) | Year 5 (FY 2030) | Implied Share Price |
|---|---|---|---|---|---|---|
| Bull Case Scenario | $11.50 – $14.50 | |||||
| Consolidated Revenue ($M) | $29.50 | $54.00 | $61.50 | $69.00 | $77.00 | |
| Gross Margin (%) | 44.5% | 46.0% | 47.0% | 48.0% | 48.5% | |
| Consolidated EBITDA ($M) | $2.30 | $6.80 | $8.90 | $10.70 | $12.30 | |
| Base Case Scenario | $5.25 – $7.00 | |||||
| Consolidated Revenue ($M) | $12.50 | $15.50 | $18.50 | $21.50 | $24.50 | |
| Gross Margin (%) | 41.5% | 42.5% | 43.5% | 44.0% | 44.5% | |
| Consolidated EBITDA ($M) | $(0.40) | $0.65 | $1.50 | $2.10 | $2.70 | |
| Bear Case Scenario | $1.25 – $2.00 | |||||
| Consolidated Revenue ($M) | $10.50 | $9.00 | $8.20 | $7.80 | $7.40 | |
| Gross Margin (%) | 36.5% | 35.0% | 34.0% | 33.5% | 33.0% | |
| Consolidated EBITDA ($M) | $(1.50) | $(2.30) | $(2.60) | $(2.90) | $(3.10) |
The bull case assumes the pending acquisition target is successfully integrated by Q4 2026, with the transaction financed through a balanced combination of non-dilutive equity and low-interest bank debt.[7, 8] Under this scenario, the target’s baseline operating margins are preserved, and cost synergies help expand combined gross margins to 48.5%.
Additionally, organic growth is driven by the high-volume production of diagnostics test-strip electrodes starting in 2027, along with rapid expansion of smart textile wearables at the South Yorkshire facility.[1] The combined business reaches sustained profitability, and the stock benefits from its inclusion in the Russell Microcap Index.[10]
The base case assumes the proposed acquisition target fails to close due to due diligence or financing issues.[8] Growth remains purely organic, with the company expanding its core sensor sales and scaling its UK and European operations.[1, 13] The South Yorkshire facility begins volume production by mid-2027, and the medical wearable pipeline achieves steady commercial adoption.[1]
Under this model, the company achieves GAAP break-even and positive Adjusted EBITDA by Year 2, with revenue growing at a 15% CAGR from organic projects.
The bear case assumes the acquisition is aborted, and Interlink loses its primary 23% customer due to competitive displacement.[6, 8] It also assumes the smart textile wearable pipeline experiences clinical and regulatory delays, and silver raw material inflation remains high.[1, 12]
Under this model, gross margins compress to 33.0%, cash reserves are depleted, and the company is forced to seek dilutive emergency equity financing.
To evaluate Interlink’s risk-return profile, the company was assessed across five fundamental dimensions of operational and financial strength.
| Strategic Evaluation Pillar | Score | Key Strengths & Tailwinds | Key Risks & Structural Headwinds |
|---|---|---|---|
| Management Alignment & Governance | 8 / 10 | CEO Steven N. Bronson has over 15 years of tenure and holds a 75.22% equity stake, aligning his interest with long-term share performance.[29, 31] | High concentration of voting control limits minority shareholder influence, and the CEO maintains leadership roles at other public entities.[20, 29] |
| Technology IP & R&D Defensibility | 9 / 10 | Supported by 49 issued patents, 14 pending applications, and proprietary formulations for conductive transfer inks.[3, 20] | Fast-moving industry standards require continuous R&D spending to maintain competitive technical advantages.[18, 32] |
| Market Opportunity & Secular Tailwinds | 8 / 10 | Positions the company to capture demand in high-growth areas, including medical wearables and printed electronics.[1, 16] | Fragmented competitive landscape with large, highly capitalized tier-one competitors.[16, 19] |
| Financial Health & Capital Access | 5 / 10 | High current ratio of 3.63x and low long-term debt.[25, 27] | Limited absolute cash position ($2.11 million) and negative operating cash flow constrain organic expansion.[1, 28] |
| M&A Execution & Integration Risk | 3 / 10 | The pending acquisition would scale the company's size and provide baseline profitability.[7] | Reverse-takeover-scale transaction introduces high integration and operational execution risks.[7, 8] |
The investment thesis for Interlink Electronics centers on an asymmetric micro-cap turnaround.[1, 7] Historically, Interlink’s valuation has been constrained by a sub-scale organic business model that generated persistent operating losses.[4, 21] However, the current strategy addresses these limitations through a combination of inorganic scale expansion and high-margin product commercialization.[1, 7]
If executed successfully, the acquisition of the target company would transform Interlink’s financial profile by adding $33 million in profitable revenue and $4 million in EBITDA, instantly scaling the top line and introducing healthy operational cash flow.[7] At the same time, the transition of the medical wearables and point-of-care test strip electrode programs from the R&D stage to clinical trials and volume production by late 2026/2027 should support organic gross margin expansion.[1] The cleanup of the capital structure through preferred share conversion and the stock's inclusion in the Russell Microcap Index provide supportive technical tailwinds.[5, 10]
However, the investment case carries significant execution risks. The consolidated enterprise is exposed to binary customer concentration (23% of accounts receivable) [6] and geopolitical supply chain sensitivities in China.[5] Financing the pending acquisition could also result in substantial shareholder dilution.[7]
Consequently, Interlink’s risk-reward profile is best understood as a dual-catalyst micro-cap option. While the business carries notable execution risks, the combination of organic medical commercialization, index reconstitution, and transformational M&A potential offers substantial upside if management executes its strategic goals.[1, 7, 10]
As of late June 2026, Interlink’s price action indicates a technical transition from a long-term decline to near-term consolidation and accumulation.[27, 28]
Technical Moving Average Profile:
- Current Share Price: $4.61 [27]
- 50-day Simple Moving Average (SMA): $4.06 [27]
- 200-day Simple Moving Average (SMA): $4.37 [27]
The stock price crossed above its 200-day moving average in mid-June 2026, marking a positive shift in long-term momentum.[33]
Price Trading Range (52-Week Profile):
- 52-Week Trading High: $10.10 [27, 28]
- 52-Week Trading Low: $2.66 [27, 28]
- Relative Strength Index (RSI): 57.70 [27]
An RSI of 57.70 suggests the stock is in a constructive consolidation phase, maintaining upward momentum without entering overbought territory.[27]
The stock experienced a significant volume spike on May 20, 2026, with 168,710 shares traded.[34] This occurred immediately following the company’s corporate presentation at the 16th Annual LD Micro Invitational in Los Angeles on May 19, 2026.[35]
The presentation, which detailed the proposed acquisition, helped spark initial trading interest.[7, 35] This has established several key technical levels:
| Technical Trading Zone | Price Level / Support-Resistance Band |
|---|---|
| Primary Resistance Level | $5.30 – $5.40 (Consists of late May and early June consolidation peaks).[34] |
| Major Breakout Resistance | $6.05 (The absolute local high achieved during the May 26 volume surge).[34] |
| Primary Support Level | $4.25 – $4.35 (Aligns with the 200-day moving average).[27, 28, 34] |
| Major Support Level | $4.02 – $4.06 (Aligns with the ascending 50-day moving average).[27, 28] |
In the short term, LINK is expected to trade within a range bounded by support at $4.25 and primary resistance at $5.40.[34] The stock's technical base is supported by its inclusion in the Russell Microcap Index, effective after the market close on June 26, 2026.[10, 11] This index reconstitution is expected to drive steady, passive buying pressure as index-tracking micro-cap funds establish benchmark positions.[36]
However, because the public float remains low (averaging 31,213 shares over a 20-day trailing period), the stock is susceptible to elevated bid-ask spreads and volatility.[27] Sharp price movements are likely to be driven by fundamental updates, such as progress toward a definitive acquisition agreement or clinical trial milestones for its diagnostics programs.[1, 8]
These catalysts are supported by a consensus price target of $8.67, representing standard analyst forecasts of substantial upside.[37, 38]
View Interlink Electronics, Inc. (LINK) stock page
Loading the interactive version of this report…